| Income Statement | 2025-06-30 | |||
|---|---|---|---|---|
| Research and development | 21,491 | |||
| General and administrative | 7,093 | |||
| Total operating expenses | 28,584 | |||
| Loss from operations | -28,584 | |||
| Other expense | -2 | |||
| Interest income | 3,251 | |||
| Income tax expense | 0 | |||
| Change in fair value of contingent value right liability | 0 | |||
| Total other income (expense), net | 3,249 | |||
| Net loss | -25,335 | |||
| Net unrealized losses on marketable securities | -161 | |||
| Comprehensive loss | -25,496 | |||
| Net loss per share, basic | -0.49 | |||
| Net loss per share, diluted | -0.49 | |||
| Weighted average number of shares outstanding, basic | 52,105,052 | |||
| Weighted-average shares outstanding, diluted | 52,105,052 | |||
Enliven Therapeutics, Inc. (IMRA)
Enliven Therapeutics, Inc. (IMRA)